Welcome to our dedicated page for InMed Pharmaceuticals Common Shares news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals Common Shares stock.
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a leading Canadian clinical-stage biopharmaceutical company at the forefront of cannabinoid research and development. Specializing in the creation of novel therapies, InMed harnesses the extensive pharmacology of cannabinoids, combined with cutting-edge drug delivery systems.
InMed's innovative approach includes a robust product pipeline featuring:
- INM-755: A topical cream for the treatment of epidermolysis bullosa, a rare skin condition.
- INM-088: An ophthalmic formulation targeting glaucoma to preserve retinal function.
- INM-901: A promising treatment for Alzheimer's disease, showing multiple mechanisms of action to improve cognitive and memory functions.
- INM-089: Aimed at treating age-related macular degeneration (AMD), focusing on retinal protection and functionality.
The company's proprietary IntegraSyn manufacturing system ensures the production of high-quality pharmaceutical-grade cannabinoids, positioning them as a key player in the industry.
InMed's recent achievements include:
- Completion of a Phase 2 clinical trial for INM-755.
- Initiation of two new preclinical programs for Alzheimer's and AMD.
- Strong financial performance with significant revenue growth from its subsidiary BayMedica, which supplies rare cannabinoids to the health and wellness sector.
InMed's commitment to advancing cannabinoid science is evident through its strategic partnerships, rigorous research, and innovative product development, making significant strides in treating diseases with high unmet medical needs. For more information, visit www.inmedpharma.com.
Rhea-AI Summary
InMed Pharmaceuticals has selected INM-901 as its lead Alzheimer's disease drug candidate after positive results from proof-of-concept studies. INM-901 showed potential in targeting biological pathways associated with Alzheimer's and demonstrated favorable results in preclinical studies. The next stage will include advanced preclinical studies and drug development activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
70.52%
Tags
-
News
Rhea-AI Summary
InMed Pharmaceuticals Inc. reports $4.1M revenues in fiscal year 2023, a 280% increase over the previous year, and $2.3M revenues in fiscal Q4 2023, a 123% increase QoQ. Completed Phase 2 Clinical Trial for anti-itch cream. Launches INM-900 series program targeting neurodegenerative diseases. Cash, cash equivalents, and short-term investments at $9.0M as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals received notice from Nasdaq regarding its common shares falling below the minimum bid price requirement. The company has 180 days to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
Rhea-AI Summary
InMed Pharmaceuticals Inc. to participate in H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) reports $2.3M unaudited revenues in Q4 2023, marking a 123% QoQ increase. The company's subsidiary BayMedica LLC achieved a third consecutive quarter of significant revenue growth. With optimized manufacturing processes and increased production, BayMedica is positioned as a leading supplier of bioidentical rare cannabinoids to the Health and Wellness market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
News
Rhea-AI Summary
InMed Pharmaceuticals announced safety and efficacy results from its Phase 2 clinical trial for the treatment of symptoms related to EB. The trial showed positive indication of enhanced anti-itch activity for INM-755 CBN cream. InMed will pursue strategic partnership opportunities for INM-755 in EB and other itch-related skin conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.56%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals announced results from a neurodegenerative disease study, demonstrating the potential of a specific rare cannabinoid to reduce amyloid toxicity and tau protein expression while enhancing neuronal cell growth. This could be a significant development in the treatment of neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) announces participation in upcoming virtual investor events. CEO Eric A. Adams and VP Jerry Griffin will co-host a presentation on addressing the increasing demand for rare cannabinoids. Investors can register for the Tribe Public Webinar on May 31 and the Investor Summit on June 1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
FAQ
What is the current stock price of InMed Pharmaceuticals Common Shares (INM)?
The current stock price of InMed Pharmaceuticals Common Shares (INM) is $4.66 as of December 24, 2024.
What is the market cap of InMed Pharmaceuticals Common Shares (INM)?
The market cap of InMed Pharmaceuticals Common Shares (INM) is approximately 3.3M.
What is InMed Pharmaceuticals Inc.?
InMed Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in the research, development, and manufacturing of novel cannabinoid-based therapies.
What products are in InMed's pipeline?
InMed's product pipeline includes INM-755 for epidermolysis bullosa, INM-088 for glaucoma, INM-901 for Alzheimer's disease, and INM-089 for age-related macular degeneration.
What is the IntegraSyn manufacturing system?
IntegraSyn is InMed's proprietary manufacturing system designed to produce high-quality pharmaceutical-grade cannabinoids efficiently.
What recent achievements has InMed made?
Recent achievements include completing a Phase 2 clinical trial for INM-755, launching preclinical programs for Alzheimer's and AMD, and significant revenue growth from BayMedica.
Who are InMed's strategic partners?
InMed collaborates with various pharmaceutical and biotechnology companies to advance its cannabinoid research and development efforts.
What financial outlook does InMed have?
InMed has shown strong financial performance, with revenue growth from its subsidiary BayMedica and a solid cash position to support its ongoing operations.
What diseases does InMed target?
InMed targets diseases with high unmet medical needs, including epidermolysis bullosa, glaucoma, Alzheimer's disease, and age-related macular degeneration.
How does InMed contribute to the health and wellness industry?
Through its subsidiary BayMedica, InMed supplies rare cannabinoids to brands within the health and wellness industry, driving revenue growth and expanding market reach.
Where can I find more information about InMed?
For more information, visit InMed's websites at www.inmedpharma.com and www.baymedica.com.
What are the future plans for InMed's product development?
InMed plans to further develop its proprietary small molecule drug candidates, continue preclinical and clinical trials, and explore new therapeutic areas.
InMed Pharmaceuticals Inc. Common Shares
Nasdaq:INM
INM Rankings
INM Stock Data
3.35M
713.96k
0.87%
Biotechnology
Pharmaceutical Preparations
United States of America
VANCOUVER